Alembic Pharmaceuticals has received final approval from the USFDA for its Lamotrigine orally disintegrating tablets used in the treatment of various seizure disorders.

Lamotrigine is primarily used to treat seizures. According to IQVIA data, the estimated market size for the product is $27 ...

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Lamotrigine Orally Disintegrating Tablets USP, 25 mg, ...

INSTI, two-drug regimen to demonstrate non-inferiority and a similar safety profile at Week 48 to BIC/FTC/TAF in adults living with HIV-1 who had not previously received antiretroviral ...

Dr Albina Maksimiuk inappropriately prescribed medication while working at Dublin clinics, fitness-to-practise inquiry hears ...

Though increasingly prescribed in the U.S., a 2025 study linked gabapentin prescriptions for chronic low back pain with ...

Recently published Drug-Resistant Epilepsy Market Insights report includes a comprehensive understanding of current treatment ...

DelveInsight forecasts a rise in the drug-resistant epilepsy market from 2025 to 2034, driven by higher prevalence, improved diagnosis, treatment advances, aging demographics, increased awareness ...

Indoco Remedies Ltd shares surged after receiving USFDA approval for Brivaracetam Oral Solution. | One of India's leading Digital News Agency offering Breaking News round the clock. Why not read our ...

The global epilepsy drugs market is poised for robust growth, estimated to increase from US$ 8.29 billion in 2025 to US$ ...

Indoco Remedies added 2.61% to Rs 204.55 after it has received final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Brivaracetam Oral ...